TEL AVIV, Israel & PARSIPPANY, N.J., September 28, 2023 Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced changes to its leadership team. Sven Dethlefs, Executive Vice President, North America Commercial, will leave Teva on November 17, 2023, and Christine (Chris) Fox, who most recently served as Global President, Gene Therapies at Novartis will be the new head of Teva’s U.S. Commercial Business. "On behalf of the Teva Board of Directors and our executive management team
Teva Pharmaceuticals And Alvotech Provide Update On Strategic Biosimilars Partnership menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , a global leader in generic and innovative medicines and Alvotech , a global biotech company specializing in the.
Alvotech and Teva Secure U S License Date for AVT04, a Proposed Biosimilar to Stelara® finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.
Complete Response Letter Received for AVT02 Biologics License Application streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.